SCHEMBL5458309

SCHEMBL5458309

O=C(Cc1ccc(Cl)cc1)N1CCN(c2ccc3c(c2)CCN(C2CCCC2)CC3)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 1/20 0.56
ME1 P48163 1/20 0.56
ME3 Q16798 1/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
GFER P55789 1/20 0.54
ATM Q13315 1/20 0.54
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HRH3 Q9Y5N1 8/20 0.51
TMEM97 Q5BJF2 5/20 0.51
SIGMAR1 Q99720 5/20 0.51
HTR1A P08908 2/20 0.51
HRH2 P25021 2/20 0.51
HRH1 P35367 2/20 0.51
CHRM4 P08173 1/20 0.51
CHRM5 P08912 1/20 0.51
ADRA2A P08913 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA1D P25100 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468405 0.90 KDM4E (0.67) ME2ME1ME3MEN1KMT2A
SCHEMBL5467837 0.89 PANK3 (0.49) ME2ME1ME3MEN1KMT2A
SCHEMBL5453428 0.88 KDM4E (0.52) ME2ME1ME3MEN1KMT2A
SCHEMBL5454869 0.87 GFER (0.58) KMT2AGFERKDM4EALDH1A1HRH3
SCHEMBL5464941 0.87 ME2 (0.58) ME2ME1ME3MEN1KMT2A
SCHEMBL5455992 0.85 HRH3 (0.53) ME2ME1ME3KDM4EALDH1A1
SCHEMBL5472454 0.84 HRH3 (0.64) KMT2AKDM4EALDH1A1HRH3TMEM97
SCHEMBL5459927 0.84 SIGMAR1 (0.49) KDM4EALDH1A1HRH3TMEM97SIGMAR1
SCHEMBL5460606 0.84 ALDH1A1 (0.53) MEN1KMT2AKDM4EALDH1A1HRH3
SCHEMBL5463790 0.81 TMEM97 (0.45) KDM4EALDH1A1HRH3TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders GLAXO GROUP LIMITED (GB) 2007-08-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185089-A1 Benzazepine derivatives for the treatment of neurological and psychiatric disorders CNR2, GRIN2C, GRIN2B ME2 720/4885ME1 1776/4885ME3 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.